Valuation
- Market cap
- —
- Revenue TTM
- $0
- Net income TTM
- $0
- P/E (trailing)
- —
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- —
Trading
- Volume
- 1,300
- Avg volume
- 6,896
- Day's range
- $0.00 – $0.00
- Shares out
- —
- Stochastic %K
- 0%
- Beta
- —
- Analysts
- —
- Price target
- —
Company profile
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an investigative formulation of inhaled interferon beta (IFN-ß') for the treatment and prevention of severe viral lung infections in high-risk patient groups. The company was incorporated in 2003 and is headquartered in Southampton, the United Kingdom.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 44 23 8051 2800
- Website
- https://www.synairgen.com
- Address
- Mailpoint 810, Southampton General Hospital Tremona Road, Southampton, United Kingdom
Latest news
No headlines yet.
